Primary File Info
Schering-Plough and Concerns about Vytorin®
Bhagwangar Dhanishtha Kika, and Smith, Matthew R., O’Rourke, J. S. (Editor)
February 12, 2018
Strategy & General Management
methods, stakeholders, stakeholder concerns, effective and timely manner, Health, financial ramifications
Clinical tests showed cholesterol drug Vytorin® was not living up to the claims of the producers, Schering-Plough and Merck. Consumers could receive a virtually equivalent drug for one-third of the cost. The problem facing Schering-Plough was to find the best methods to reach its stakeholders and ensure them that their concerns will be addressed in a timely and effective manner. This case has health, financial, and legal ramifications for stakeholders.